雾化镁联合沙丁胺醇对急诊难治性急性哮喘儿童住院率的影响:一项随机临床试验
本研究为随机双盲平行组临床试验,纳入7家加拿大三级儿科急诊、2至17岁、经口服皮质类固醇和3次吸入沙丁胺醇及异丙托溴铵治疗1小时后PRAM评分≥5分的难治性急性哮喘儿童818例。干预为3次雾化沙丁胺醇联合硫酸镁(n=410)或5.5%生理盐水安慰剂(n=408)。次要终点PRAM评分、呼吸频率、氧饱和度、收缩压及额外沙丁胺醇治疗次数均无显著差异。结论不支持在急诊难治性急性哮喘儿童中使用雾化镁联合沙丁胺醇。
要点
- 雾化镁组恶心/呕吐或咽喉/鼻部不适发生17/409(4%),安慰剂组5/407(1%)。
- 研究结论不支持在急诊难治性急性哮喘儿童中使用雾化镁联合沙丁胺醇。
适用人群与场景
- 7家加拿大三级儿科急诊中,2至17岁、其他方面健康的儿童,在口服皮质类固醇和3次吸入沙丁胺醇及异丙托溴铵治疗1小时后仍处于中度至重度呼吸窘迫(PRAM评分≥5分,12分制)的难治性急性哮喘患者。
诊断标准与关键阈值
- 难治性急性哮喘定义为:经口服皮质类固醇和3次吸入沙丁胺醇及异丙托溴铵治疗1小时后,儿童呼吸评估测量(PRAM)评分≥5分(12分制)。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:随机、双盲、平行组临床试验;7家三级儿科急诊;818例随机,816例分析(镁组409例,安慰剂组407例);中位年龄5岁,63%男性。
- 干预:3次雾化沙丁胺醇联合硫酸镁(n=410) vs 3次雾化沙丁胺醇联合5.5%生理盐水安慰剂(n=408)。
- 不良事件:恶心/呕吐或咽喉/鼻部不适在镁组17/409(4%),安慰剂组5/407(1%)。
证据类型、等级与局限
- 证据类型:随机双盲平行组临床试验;原文未提及证据等级或推荐强度。
- 局限:原文未明确列出局限性;试验注册号NCT01429415。
对床旁实践的改变
- 对于急诊中经初始治疗(口服皮质类固醇和3次吸入沙丁胺醇及异丙托溴铵)后仍处于中度至重度呼吸窘迫(PRAM≥5分)的2至17岁急性哮喘儿童,不推荐常规加用雾化镁联合沙丁胺醇以降低住院率。
- 该结论不适用于原文未纳入的人群(如其他年龄段、非中度至重度、或未经初始治疗者),也不适用于静脉镁的使用决策。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: While intravenous magnesium decreases hospitalizations in refractory pediatric acute asthma, it is variably used because of invasiveness and safety concerns. The benefit of nebulized magnesium to prevent hospitalization is unknown.
OBJECTIVE: To evaluate the effectiveness of nebulized magnesium in children with acute asthma remaining in moderate or severe respiratory distress after initial therapy.
DESIGN, SETTING, AND PARTICIPANTS: A randomized double-blind parallel-group clinical trial from September 26, 2011, to November 19, 2019, in 7 tertiary-care pediatric emergency departments in Canada. The participants were otherwise healthy children aged 2 to 17 years with moderate to severe asthma defined by a Pediatric Respiratory Assessment Measure (PRAM) score of 5 or greater (on a 12-point scale) after a 1-hour treatment with an oral corticosteroid and 3 inhaled albuterol and ipratropium treatments. Of 5846 screened patients, 4332 were excluded for criteria, 273 declined participation, 423 otherwise excluded, 818 randomized, and 816 analyzed.
INTERVENTIONS: Participants were randomized to 3 nebulized albuterol treatments with either magnesium sulfate (n = 410) or 5.5% saline placebo (n = 408).
MAIN OUTCOMES AND MEASURES: The primary outcome was hospitalization for asthma within 24 hours. Secondary outcomes included PRAM score; respiratory rate; oxygen saturation at 60, 120, 180, and 240 minutes; blood pressure at 20, 40, 60, 120, 180, and 240 minutes; and albuterol treatments within 240 minutes.
RESULTS: Among 818 randomized patients (median age, 5 years; 63% males), 816 completed the trial (409 received magnesium; 407, placebo). A total of 178 of the 409 children who received magnesium (43.5%) were hospitalized vs 194 of the 407 who received placebo (47.7%) (difference, -4.2%; absolute risk difference 95% [exact] CI, -11% to 2.8%]; P = .26). There were no significant between-group differences in changes from baseline to 240 minutes in PRAM score (difference of changes, 0.14 points [95% CI, -0.23 to 0.50]; P = .46); respiratory rate (0.17 breaths/min [95% CI, -1.32 to 1.67]; P = .82); oxygen saturation (-0.04% [95% CI, -0.53% to 0.46%]; P = .88); systolic blood pressure (0.78 mm Hg [95% CI, -1.48 to 3.03]; P = .50); or mean number of additional albuterol treatments (magnesium: 1.49, placebo: 1.59; risk ratio, 0.94 [95% CI, 0.79 to 1.11]; P = .47). Nausea/vomiting or sore throat/nose occurred in 17 of the 409 children who received magnesium (4%) and 5 of the 407 who received placebo (1%).
CONCLUSIONS AND RELEVANCE: Among children with refractory acute asthma in the emergency department, nebulized magnesium with albuterol, compared with placebo with albuterol, did not significantly decrease the hospitalization rate for asthma within 24 hours. The findings do not support use of nebulized magnesium with albuterol among children with refractory acute asthma.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01429415.
参考来源
- Schuh S, Sweeney J, Rumantir M, et al. Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial. JAMA. 2020. PMID: 33231663. doi:10.1001/jama.2020.19839
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。